(Q37724378)

22 August 2017

1 reference

title

Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer (English)

1 reference

22 August 2017

1 reference

Joanne Edwards

1

1 reference

PubMed ID

20367532

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

1 reference

22 August 2017

19

1 reference

22 August 2017

5

1 reference

22 August 2017

605-614

1 reference

22 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The genetics of castration-resistant prostate cancer: what can the germline tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Treatment of bone metastases and bone pain with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Osteoblasts in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Castration-resistant prostate cancer: locking up the molecular escape routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Targeting Src signaling in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The current state of hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Cancer treatment-induced bone loss in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src as a therapeutic target in men with prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Osteoclasts express high levels of pp60c-src in association with intracellular membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src kinase activity is essential for osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

21 January 2018

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Quality of surveillance for stage I testis cancer in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Genomic strategy for targeting therapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Genomic approaches to outcome prediction in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003789388

10.1517/13543781003789388

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20367532